Royce & Associates LP raised its stake in shares of Apyx Medical Corporation (NASDAQ:APYX – Free Report) by 7.0% during the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 3,503,098 shares of the company’s stock after buying an additional 229,034 shares during the period. Royce & Associates LP owned 0.08% of Apyx Medical worth $8,583,000 at the end of the most recent quarter.
A number of other institutional investors and hedge funds also recently made changes to their positions in APYX. Nantahala Capital Management LLC bought a new stake in shares of Apyx Medical during the 2nd quarter worth about $14,683,414. Sei Investments Co. increased its holdings in shares of Apyx Medical by 298.6% during the 1st quarter. Sei Investments Co. now owns 598,255 shares of the company’s stock valued at $2,208,000 after acquiring an additional 448,174 shares during the last quarter. BlackRock Inc. acquired a new position in shares of Apyx Medical during the 2nd quarter valued at about $2,519,000. AIGH Capital Management LLC acquired a new position in shares of Apyx Medical during the 2nd quarter valued at about $5,066,000. Finally, Kingsview Wealth Management LLC bought a new position in shares of Apyx Medical in the 2nd quarter valued at approximately $962,000. Institutional investors and hedge funds own 55.33% of the company’s stock.
Apyx Medical Stock Down 3.4%
NASDAQ:APYX opened at $2.56 on Wednesday. The company has a current ratio of 4.95, a quick ratio of 3.85 and a debt-to-equity ratio of 3.54. Apyx Medical Corporation has a one year low of $2.25 and a one year high of $5.08. The company has a fifty day moving average price of $2.71 and a 200 day moving average price of $3.54.
Analyst Ratings Changes
Several equities research analysts recently weighed in on the company. Maxim Group started coverage on Apyx Medical in a report on Tuesday, September 29th. They issued a “buy” rating and a $6.00 target price for the company. Weiss Ratings reiterated a “sell (d-)” rating on shares of Apyx Medical in a report on Monday, September 21st. One investment analyst has rated the stock with a Strong Buy rating, four have assigned a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat, the company currently has an average rating of “Moderate Buy” and an average target price of $6.20.
Check Out Our Latest Analysis on Apyx Medical
Apyx Medical Company Profile
Apyx Medical Corporation is a medical technology company focused on advanced energy devices for surgical and aesthetic procedures. Its main product is the Renuvion system, which combines helium plasma with radiofrequency energy for use in procedures covered by applicable regulatory clearances. The company also supplies electrosurgical generators and related products, including through its original equipment manufacturing business. Apyx Medical was formerly known as Bovie Medical Corporation and adopted its current name in 2018.
Recommended Stories
- Five stocks we like better than Apyx Medical
- NVIDIA’s Turbulence Could Have Ripple Effects Across Quantum Computing
- Banking on AI: Can Upstart’s New Bank Plan Turn Its Stock Around?
- Amazon’s Black Friday Rush Could Kick Off a Holiday Season That Defines Its Year
- The Next Nuclear Opportunity May Be in Fuel, Not Reactors: 3 Stocks to Watch
Want to see what other hedge funds are holding APYX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Apyx Medical Corporation (NASDAQ:APYX – Free Report).
Receive News & Ratings for Apyx Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Apyx Medical and related companies with MarketBeat.com's FREE daily email newsletter.
